Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Advertisement
Sara Tolaney, MD, MPHTriple-Negative Breast Cancer | June 5, 2025
Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Lauren Dembeck, PhDTriple-Negative Breast Cancer | June 4, 2025
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Stephanie L. Graff, MDHER2 Breast Cancer | June 4, 2025
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
Lauren Dembeck, PhDTriple-Negative Breast Cancer | June 2, 2025
High CIG signature or high sTILs linked to better survival in stage I TNBC; findings support further prognostic evaluation.
Lauren Dembeck, PhDTriple-Negative Breast Cancer | May 31, 2025
Sacituzumab tirumotecan showed a 71% ORR and manageable safety in first-line advanced TNBC, regardless of PD-L1 status.
Katie KoskoBreast Cancer News | May 15, 2025
Emiltatug ledadotin showed early clinical activity and was well tolerated in heavily pretreated patients with TNBC.
Yvette C. TerrieTriple-Negative Breast Cancer | May 6, 2025
Darolutamide did not meet the clinical benefit endpoint in AR-positive TNBC, per findings from the phase II START trial.
David Winchester, MDBreast Cancer News | May 10, 2025
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
David Winchester, MDBreast Cancer News | May 5, 2025
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Brandon TwyfordTriple-Negative Breast Cancer | April 21, 2025
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
Leah LawrenceTriple-Negative Breast Cancer | April 15, 2025
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Leah LawrenceTriple-Negative Breast Cancer | April 9, 2025
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Yvette C. TerrieTriple-Negative Breast Cancer | April 8, 2025
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Jordana JampelTriple-Negative Breast Cancer | March 25, 2025
Researchers aimed to evaluate the roll of ERCC1 expression in predicting response to adjuvant chemotherapy for TNBC.
Rob DillardTriple-Negative Breast Cancer | March 25, 2025
A novel method can assess which patients with TNBC could benefit from immunotherapy.
Rob DillardTriple-Negative Breast Cancer | March 25, 2025
New research shows that selenium, a mineral commonly found in Brazil nuts, could hold the key to stopping the spread of TNBC.
Laura LitwinBreast Cancer News | March 25, 2025
Cancer researchers at Brigham and Women’s Hospital have identified a potential new method for the treatment of TNBC.
Rob DillardTriple-Negative Breast Cancer | March 25, 2025
New research suggests ICI therapy improves efficacy outcomes in early-stage breast cancer over adjuvant therapy.
Dr. Margaret Gatti-MaysBreast Cancer News | March 26, 2025
Dr. Margaret Gatti-Mays explains how to address the most pressing questions in triple-negative breast cancer treatments.
Dr. Margaret Gatti-MaysTriple-Negative Breast Cancer | March 26, 2025
Dr. Gatti-Mays discusses how treatment for triple-negative breast cancer has evolved in recent years.
Advertisement